Top 10 Psychedelic-Assisted Therapy Papers

Sessa argues for a realistic relationship between psychiatry and psychedelics. The commentary is useful because it pushes against both moral panic and utopian overreach, framing psychedelic-assisted therapy as a clinical practice that needs sober evidence and professional standards.

Belouin and Henningfield use the field's turbulent history to explain the modern revival. The paper is valuable because it connects research progress to regulation, public perception, and the policy decisions that will shape whether psychedelic medicines can be studied and delivered responsibly.

Nichols, Johnson, and Nichols review psychedelics as a possible new medical paradigm. The paper is useful because it combines clinical findings with cellular and anti-inflammatory mechanisms, showing why psychedelic-assisted therapy cannot be understood through psychology alone.

Guimaraes and Hallak review the therapeutic evidence and mechanisms for serotonergic hallucinogens. The paper matters because it covers LSD, psilocybin, and ayahuasca across substance use, depression, and anxiety while keeping biological and psychological explanations together.

This modern LSD-assisted psychotherapy trial reopened clinical work on LSD for anxiety linked to life-threatening illness. Its small sample limits conclusions, but the study is important because it showed the treatment could be delivered safely in a contemporary therapeutic protocol.

This Johns Hopkins cancer-distress trial is central to the modern psilocybin therapy literature. It matters because symptom improvements were paired with changes in meaning, optimism, death acceptance, and quality of life, outcomes especially relevant in serious illness.

Reiche and colleagues review decades of psychedelic trials for anxiety and depression in people with life-threatening disease. The paper is useful because it pulls older LSD work and modern psilocybin studies into one view while making the evidence limits explicit.

This large ayahuasca survey adds a naturalistic perspective to psychedelic-assisted therapy discussions. It does not prove clinical efficacy, but it shows how ayahuasca use relates to wellbeing, alcohol use, and acute subjective effects in a broad international sample.

Wolff and colleagues translate psychedelic therapy into a cognitive-behavioral model of acceptance. The paper is interesting because it explains how relaxed beliefs, emotional breakthrough, and reduced avoidance could turn an acute experience into longer-term behaviour change.

This cost-effectiveness model asks whether MDMA-assisted psychotherapy for chronic PTSD could be economically viable, not just clinically promising. It is useful because access decisions often depend on cost, care intensity, and health-system value as much as symptom change.